Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Serum Level-targeted Study Investigating the Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Patients With Various Refractory Malignancies

NCT00050687 is registered in ClinicalTrials.gov with Titan Pharmaceuticals as lead sponsor.

NCT NCT00050687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00050687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Serum Level-targeted Study Investigating the Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Patients With Various Refractory Malignancies
Lead sponsor
Titan Pharmaceuticals
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2001
Completion date
March 31, 2005
Enrollment
Not reported
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bladder neoplasms, lymphoma, multiple myeloma, prostatic neoplasms